Device/Diagnostics Quarterly Deal Statistics, Q4 2013

A look at financing, M&A, and alliance activity, October–December 2013

Device companies finished 2013 strong, raising $1.2 billion in Q4, the highest quarter total of the year. CVS Caremark’s $2.1 billion buy of Apria’s infusion therapy business was the largest M&A of the year, and late-stage venture rounds dominated the $423 million total in diagnostics funding.

Thirty-six financings brought in $1.2 billion during 2013’s fourth quarter, almost double Q3’s $644 million total, making it the most lucrative quarter of 2013. The majority (63%) of Q4’s dollars came in from public offerings. (See Exhibit 1.) This marks a big switch from last quarter, when 50% of the financing dollars came from late-stage venture rounds. (In Q2 late-stage private placements accounted for most of the financing dollars as well.) The fourth quarter is also the only one in which public offerings made up the majority. The total device financing for all of 2013 was $4 billion. (See Exhibit 2.) There was a steep increase in follow-on offering dollar volume, which reached $393 million in Q4, versus the $61 million in FOPO dollars in the third quarter. Integra LifeSciences Holdings Corp.’s $133 million November deal [See Deal] led that group, and the company may use some of the proceeds to fund its $235 million October acquisition of Covidien Ltd.’s now-defunct Confluent Surgical division’s sealants and adhesion barrier products [See Deal].

Exhibit 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By 

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.